Why the study?
Does ventricular enlargement and dexamethasone suppression test (DST) status predict clinical response to haloperidol in schizophrenic in-patients?
Population
24 schizophrenic in-patients, both sexes, mean age 26.62 +/- 5.26 years, diagnosed according to DSM-III-R…
Design
Cohort
Follow-up
4 weeks
Authors
Loading...
Ventricular enlargement and DST non-suppression may associate with unpredictable haloperidol response in schizophrenia; leaves open predictive utility pending prospective trials.
Does ventricular enlargement and dexamethasone suppression test (DST) status predict clinical response to haloperidol in schizophrenic in-patients?
Ventricular enlargement and DST non-suppression may be associated with more unpredictable clinical outcomes in schizophrenic patients treated with haloperidol, though definitive differences were not established.
Mauri et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: